Plasma-derived mannose-binding lectin shows a direct interaction with C1-inhibitor

Molecular Immunology

Volumn 58, Issue 2, 2014, Pages 187-193

  Keizer, Mischa P ^a   Kamp, Angela M ^a   Brouwer, Nannette ^a   van de Wetering, Marianne D ^a   Wouters, Diana ^a   Kuijpers, Taco W ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

C1 inhibitor; Functionality; MBL substitution; Plasma derived MBL; Pre activated MASPs

Indexed keywords

ALPHA 2 MACROGLOBULIN; COMPLEMENT COMPONENT C1R; COMPLEMENT COMPONENT C1S; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE; MANNOSE BINDING LECTIN; MANNOSE BINDING LECTIN MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE 2 COMPLEMENT COMPONENT C1 INHIBTOR COMPLEX; MULTIPROTEIN COMPLEX; PLASMA DERIVED MANNOSE BINDING LECTIN; SEROTRANSFERRIN; TRANSFERRIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; COMPLEMENT ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; SIGNAL TRANSDUCTION;

ALTERNATIVE PATHWAY; AP; C1-INH; C1-INHIBITOR; CLASSICAL PATHWAY; CP; FUNCTIONALITY; HIGH PERFORMANCE ELISA BUFFER; HPE; LECTIN PATHWAY; LP; MANNAN BINDING LECTIN; MASPS; MASS-SPEC; MASS-SPECTROMETRY; MBL; MBL ASSOCIATED SERINE PROTEASES; MBL-SUBSTITUTION; MBL/MASP/C1-INH; MMC; PAB; PDMBL; PLASMA-DERIVED MBL; POLYCLONAL ANTIBODIES; POLYHRP; POLYMERIZED HORSERADISH PEROXIDASE; PRE-ACTIVATED MASPS; RECOMBINANT HUMAN MASP-2; RECOMBINANT HUMAN MBL; RHMASP-2; RHMBL; TERMINAL PATHWAY; TETRAMETHYLBENZIDINE; TMB; TP;

BLOOD PROTEINS; CHILD; COMPLEMENT C1 INHIBITOR PROTEIN; COMPLEMENT C4; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MANNOSE-BINDING LECTINS; MANNOSE-BINDING PROTEIN-ASSOCIATED SERINE PROTEASES; MULTIPROTEIN COMPLEXES; PROTEIN BINDING; TITRIMETRY;

EID: 84890889745     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2013.11.022     Document Type: Article

References (25)

1. Alexander S., Nieder M., Zerr D.M., Fisher B.T., Dvorak C.C., Sung L. Prevention of bacterial infection in pediatric oncology: what do we know, what can we learn?. Pediatr. Blood Cancer 2012, 59:16-20.
2. Basu S.K., Fernandez I.D., Fisher S.G., Asselin B.L., Lyman G.H. Length of stay and mortality associated with febrile neutropenia among children with cancer. J. Clin. Oncol. 2005, 23:7958-7966.
3. Bos I.G., Lubbers Y.T., Roem D., Abrahams J.P., Hack C.E., Eldering E. The functional integrity of the serpin domain of C1-inhibitor depends on the unique N-terminal domain, as revealed by a pathological mutant. J. Biol. Chem. 2003, 278:29463-29470.
4. Breevoort van B.D., van Agtmaal E.L., Dragt B.S., Gebbinck J.K., Dienava-Verdoold I., Kragt A., Bierings R., Horrevoets A.J., Valentijn K.M., Eikenboom J.C., Fernandez-Borja M., Meijer A.B., Voorberg J. Proteomic screen identifies IGFBP7 as a novel component of endothelial cell-specific Weibel-Palade bodies. J. Proteome Res. 2012, 11:2925-2936.
5. Brouwer N., Dolman K.M., van Z.R., Nieuwenhuys E., Hart M., Aarden L.A., Roos D., Kuijpers T.W. Mannan-binding lectin (MBL)-mediated opsonization is enhanced by the alternative pathway amplification loop. Mol. Immunol. 2006, 43:2051-2060.
6. Brouwer N., Frakking F.N., van de Wetering M.D., van H.M., Hart M., Budde I.K., Strengers P.F., Laursen I., Houen G., Roos D., Jensenius J.C., Caron H.N., Dolman K.M., Kuijpers T.W. Mannose-binding lectin (MBL) substitution: recovery of opsonic function in vivo lags behind MBL serum levels. J. Immunol. 2009, 183:3496-3504.
7. Bultink I.E., Hamann D., Seelen M.A., Hart M.H., Dijkmans B.A., Daha M.R., Voskuyl A.E. Deficiency of functional mannose-binding lectin is not associated with infections in patients with systemic lupus erythematosus. Arthritis Res. Ther. 2006, 8:R183.
8. Dahl M.R., Thiel S., Matsushita M., Fujita T., Willis A.C., Christensen T., Vorup-Jensen T., Jensenius J.C. MASP-3 and its association with distinct complexes of the mannan-binding lectin complement activation pathway. Immunity 2001, 15:127-135.
9. Dommett R., Chisholm J., Turner M., Bajaj-Elliott M., Klein N.J. Mannose-binding lectin genotype influences frequency and duration of infectious complications in children with malignancy. J. Pediatr. Hematol. Oncol. 2013, 35:69-75.
10. Frakking F.N., Brouwer N., van de Wetering M.D., Budde I.K., Strengers P.F., Huitema A.D., Laursen I., Houen G., Caron H.N., Dolman K.M., Kuijpers T.W. Safety and pharmacokinetics of plasma-derived mannose-binding lectin (MBL) substitution in children with chemotherapy-induced neutropaenia. Eur. J. Cancer 2009, 45:505-512.
11. Gal P., Dobo J., Zavodszky P., Sim R.B. Early complement proteases: C1r, C1s and MASPs. A structural insight into activation and functions. Mol. Immunol. 2009, 46:2745-2752.
12. Kerr F.K., Thomas A.R., Wijeyewickrema L.C., Whisstock J.C., Boyd S.E., Kaiserman D., Matthews A.Y., Bird P.I., Thielens N.M., Rossi V., Pike R.N. Elucidation of the substrate specificity of the MASP-2 protease of the lectin complement pathway and identification of the enzyme as a major physiological target of the serpin, C1-inhibitor. Mol. Immunol. 2008, 45:670-677.
13. Laursen I. Mannan-binding lectin (MBL) production from human plasma. Biochem. Soc. Trans. 2003, 31:758-762.
14. Laursen I., Houen G., Hojrup P., Brouwer N., Krogsoe L.B., Blou L., Hansen P.R. Second-generation nanofiltered plasma-derived mannan-binding lectin product: process and characteristics. Vox Sang. 2007, 92:338-350.
15. Laursen I., Hojrup P., Houen G., Christiansen M. Characterisation of the 1st SSI purified MBL standard. Clin. Chim. Acta 2008, 395:159-161.
16. Matsushita M., Fujita T. Activation of the classical complement pathway by mannose-binding protein in association with a novel C1s-like serine protease. J. Exp. Med. 1992, 176:1497-1502.
17. Matsushita M., Endo Y., Fujita T. Cutting edge: complement-activating complex of ficolin and mannose-binding lectin-associated serine protease. J. Immunol. 2000, 164:2281-2284.
18. Megyeri M., Harmat V., Major B., Vegh A., Balczer J., Heja D., Szilagyi K., Datz D., Pal G., Zavodszky P., Gal P., Dobo J. Quantitative characterization of the activation steps of mannan-binding lectin (MBL)-associated serine proteases (MASPs) points to the central role of MASP-1 in the initiation of the complement lectin pathway. J. Biol. Chem. 2013, 288:8922-8934.
19. Nilsson B., Nilsson E.K. The tick-over theory revisited: is C3 a contact-activated protein?. Immunobiology 2012, 217:1106-1110.
20. Petersen S.V., Thiel S., Jensen L., Vorup-Jensen T., Koch C., Jensenius J.C. Control of the classical and the MBL pathway of complement activation. Mol. Immunol. 2000, 37:803-811.
21. Petersen S.V., Thiel S., Jensen L., Steffensen R., Jensenius J.C. An assay for the mannan-binding lectin pathway of complement activation. J. Immunol. Methods 2001, 257:107-116.
22. Piersma S.R., Broxterman H.J., Kapci M., de Haas R.R., Hoekman K., Verheul H.M., Jimenez C.R. Proteomics of the TRAP-induced platelet releasate. J. Proteomics 2009, 72:91-109.
23. Sorensen R., Thiel S., Jensenius J.C. Mannan-binding-lectin-associated serine proteases, characteristics and disease associations. Springer Semin. Immunopathol. 2005, 27:299-319.
24. Tan S.M., Chung M.C., Kon O.L., Thiel S., Lee S.H., Lu J. Improvements on the purification of mannan-binding lectin and demonstration of its Ca(2+)-independent association with a C1s-like serine protease. Biochem. J. 1996, 319(Pt 2):329-332.
25. Valdimarsson H., Vikingsdottir T., Bang P., Saevarsdottir S., Gudjonsson J.E., Oskarsson O., Christiansen M., Blou L., Laursen I., Koch C. Human plasma-derived mannose-binding lectin: a phase I safety and pharmacokinetic study. Scand. J. Immunol. 2004, 59:97-102.